Phase 3 outcomes from NEJM SURMOUNT-1, SURPASS-2, STEP-1, and Lancet Orforglipron oral GLP-1 trials—plus hepatic dawn phenomenon physiology, 15-minute post-meal GLUT4 walks, and first-30-day Type 2 Diabetes remission protocols. Explore 704 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
BE between 50-mg acarbose and 500-mg metformin as an FDC and loose combination was established.
Molnupiravir could be a useful agent in non-pregnant unvaccinated adults with COVID-19 who are at increased risk of severity including hospitalization.
Increased visit-to-visit variability in HbA1c and fasting glycemia is associated with a greater risk of severe hypoglycemic events in T2DM patients.
The baseline and trajectories of the TyG index were significantly associated with the occurrence of MACEs in patients with T2DM.
The risk of gastrointestinal side effects such as abdominal pain, nausea and diarrhea is higher in type 2 diabetes patients treated with metformin compared to other antidiabetic drugs.
The GZFL formula as add-on treatment can improve the ovulation and pregnancy rates in women with PCOS.
Importantly, more well-designed RCTs are needed to validate the outcomes and verify the treatment value for clinical purposes..
There was no significant correlation between fracture risk and metformin application in T2DM patients.
TRT slightly improved the lean muscle and LDL in men with obesity having LTLs but did not affect the blood pressure.
These findings suggest that in the high-risk population of older men with obesity and hypogonadism, testosterone replacement may improve cognitive function with lifestyle behaviors controlled via lifestyle intervention...
Both GLP-1 RAs comparably affected body weight, energy and macronutrient intake.
Anagliptin affected HIC levels according to HIC baseline levels.
Metformin treatment had a small positive effect on BMC and BMD in the peripheral skeleton and reduced weight gain compared with placebo in insulin-treated patients with T2DM.
After 8 weeks of treatment, the percentage changes from baseline in non-HDL-C (-4.4% vs +0.6%; p = 0.02) and triglycerides (-18.5% vs +0.9%; p 2 ), or without diabetes.
Adding lixisenatide to BI significantly reduced HbA1c and 2-h PPG levels in both Asian and white participants with type 2 diabetes.
The optimal intervention should be targeted to cognitive decline in the early stages of dementia.
In INSTRIDE 1 and INSTRIDE 2, similar immunogenicity profiles were observed for MYL-1501D and reference insulin glargine in patients with type 1 diabetes and type 2 diabetes, respectively.
In comparison with placebo, liraglutide induced weight loss (3.38 kg, 95% CI -5.29; -1.48, P 0.08).
Dapagliflozin reduced the risk of a negative balance in the lean-to total mass ratio [OR: 0.16 (95% CI: 0.05 to 0.45); p < 0.001] even after adjustment for baseline lean-to total mass ratio, waist circumference, HOMAIR, HbA1c,...
Dasiglucagon provided rapid and effective reversal of low blood sugar in adults with type 1 diabetes, with safety and tolerability similar to those reported for reconstituted glucagon injection.
Henagliflozin 5 mg and 10 mg as single-drug treatment provided effective glycaemic control, reduced body weight and blood pressure, and was generally well tolerated.
The PFS benefit appears clinically significant over fulvestrant alone, with a 7.9 months, non-significant, improvement in overall survival.
Treatment with GLP-1RAs for obesity and diabetes does not increase the risk of breast neoplasms.
In older, obese hypogonadal men, adding testosterone for 6 months to lifestyle therapy does not further improve overall physical function.
There are no significant differences motivated by the study design.
Our meta-analysis indicated that metformin may be a independent protective factor for cancer risk in T2DM patients.
Among investigator-defined hypoglycaemic events (linagliptin: 17.3%; placebo: 12.7%; odds ratio 1.48, P = 0.337), none were severe.
Here we describe increased serum glucose levels as a novel independent predictor of baseline infliximab clearance.
Our systematic review and meta-analysis demonstrate that metformin does not reduce esophageal cancer risk in type 2 diabetes patients.
In individuals with prediabetes, 13 weeks of treatment with dapagliflozin, metformin or exercise was not associated with changes in fasting or post-OGTT glucagon concentrations.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
